Neuronetics (STIM)
(Real Time Quote from BATS)
$3.83 USD
-0.13 (-3.28%)
Updated Apr 18, 2024 11:06 AM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STIM 3.83 -0.13(-3.28%)
Will STIM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STIM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STIM
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
STIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
Other News for STIM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics announces publication of findings in Brain Stimulation
Top 5 Health Care Stocks That May Plunge In March
Neuronetics Inc Shrinks Board Following Strategy Review
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)